Neumora Therapeutics (NMRA) reported a Q3 loss Tuesday of $0.45 per diluted share, narrower than the loss of $1.14 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.39.
The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended Sept. 30.
Neumora said it had $341.3 million in cash, cash equivalents and marketable securities at the end of the quarter, which it said would enable it to fund its operating plan into mid-2026.
Price: 13.58, Change: +0.04, Percent Change: +0.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments